Decreased Risk of Anxiety in Diabetic Patients Receiving Glucagon-like Peptide-1 Receptor Agonist: A Nationwide, Population-Based Cohort Study
Background: Previous findings on using Glucagon-like peptide-1 receptor agonist (GLP1-RA) as an antidepressant were conflicting, lacking large-scale studies. We used population-based data to investigate depression and anxiety risk in diabetic patients receiving the medication.Methods: From claims re...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-02-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2022.765446/full |
| _version_ | 1818744747536154624 |
|---|---|
| author | Wen-Hsuan Tsai Fung-Chang Sung Fung-Chang Sung Fung-Chang Sung Lu-Ting Chiu Ying-Hsiu Shih Ming-Chieh Tsai Shu-I Wu Shu-I Wu |
| author_facet | Wen-Hsuan Tsai Fung-Chang Sung Fung-Chang Sung Fung-Chang Sung Lu-Ting Chiu Ying-Hsiu Shih Ming-Chieh Tsai Shu-I Wu Shu-I Wu |
| author_sort | Wen-Hsuan Tsai |
| collection | DOAJ |
| description | Background: Previous findings on using Glucagon-like peptide-1 receptor agonist (GLP1-RA) as an antidepressant were conflicting, lacking large-scale studies. We used population-based data to investigate depression and anxiety risk in diabetic patients receiving the medication.Methods: From claims records of the National Health Insurance Research Database (NHIRD) of Taiwan, we identified cohorts of 10,690 GLP1-RA users and 42,766 propensity score-matched patients without GLP1-RA use from patients with diabetes mellitus (DM) diagnosed in 2011–2017, matched by age, gender, index year, occupation, urbanization, comorbidities, and medications. Incidence, hazard ratios (HR) and 95% confidence interval (CI) of depression and/or anxiety were estimated by the end of 2017.Results: The overall combined incidence of anxiety and/or depression was lower in GLP1-RA users than in non-users (6.80 versus 9.36 per 1,000 person-years), with an adjusted HR adjusted hazard ratio (aHR) of 0.8 (95% CI: 0.67–0.95) after controlling for covariates. The absolute incidence reduction was greater in anxiety (2.13 per 1,000 person-years) than in depression (0.41 per 1,000 person-years). The treatment effectiveness was significant for women. Patients taking GLP1-RA for longer than 180 days had the incidence of anxiety reduced to 2.93 per 1,000 person-years, with an aHR of 0.41 (95%CI: 0.27–0.61), compared to non-users. Dulaglutide could significantly decrease risks of both anxiety and depression.Conclusion: Patients with DM receiving GLP1-RA therapy have a greater reduction of the risk of anxiety than that of depression. Our findings strengthen previous research that advocated possible anti-depressant or anxiolytic effects of GLP1-RA and may lead to improved treatment adherence among patients with DM. |
| first_indexed | 2024-12-18T02:49:13Z |
| format | Article |
| id | doaj.art-fb146960784741b4aa20e6b3f118d079 |
| institution | Directory Open Access Journal |
| issn | 1663-9812 |
| language | English |
| last_indexed | 2024-12-18T02:49:13Z |
| publishDate | 2022-02-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj.art-fb146960784741b4aa20e6b3f118d0792022-12-21T21:23:30ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122022-02-011310.3389/fphar.2022.765446765446Decreased Risk of Anxiety in Diabetic Patients Receiving Glucagon-like Peptide-1 Receptor Agonist: A Nationwide, Population-Based Cohort StudyWen-Hsuan Tsai0Fung-Chang Sung1Fung-Chang Sung2Fung-Chang Sung3Lu-Ting Chiu4Ying-Hsiu Shih5Ming-Chieh Tsai6Shu-I Wu7Shu-I Wu8Division of Endocrinology and Metabolism, Department of Internal Medicine, Mackay Memorial Hospital, Taipei, TaiwanManagement Office for Health Data (DryLab), Clinical Trial Research Center (CTC), China Medical University Hospital, Taichung, TaiwanDepartment of Health Services Administration, College of Public Health, China Medical University, Taichung, TaiwanDepartment of Food Nutrition and Health Biotechnology, Asia University, Taichung, TaiwanManagement Office for Health Data (DryLab), Clinical Trial Research Center (CTC), China Medical University Hospital, Taichung, TaiwanManagement Office for Health Data (DryLab), Clinical Trial Research Center (CTC), China Medical University Hospital, Taichung, TaiwanDivision of Endocrinology and Metabolism, Department of Internal Medicine, Mackay Memorial Hospital, Taipei, TaiwanDepartment of Medicine, MacKay Medical College, New Taipei City, TaiwanDepartment of Psychiatry, Mackay Memorial Hospital, Taipei, TaiwanBackground: Previous findings on using Glucagon-like peptide-1 receptor agonist (GLP1-RA) as an antidepressant were conflicting, lacking large-scale studies. We used population-based data to investigate depression and anxiety risk in diabetic patients receiving the medication.Methods: From claims records of the National Health Insurance Research Database (NHIRD) of Taiwan, we identified cohorts of 10,690 GLP1-RA users and 42,766 propensity score-matched patients without GLP1-RA use from patients with diabetes mellitus (DM) diagnosed in 2011–2017, matched by age, gender, index year, occupation, urbanization, comorbidities, and medications. Incidence, hazard ratios (HR) and 95% confidence interval (CI) of depression and/or anxiety were estimated by the end of 2017.Results: The overall combined incidence of anxiety and/or depression was lower in GLP1-RA users than in non-users (6.80 versus 9.36 per 1,000 person-years), with an adjusted HR adjusted hazard ratio (aHR) of 0.8 (95% CI: 0.67–0.95) after controlling for covariates. The absolute incidence reduction was greater in anxiety (2.13 per 1,000 person-years) than in depression (0.41 per 1,000 person-years). The treatment effectiveness was significant for women. Patients taking GLP1-RA for longer than 180 days had the incidence of anxiety reduced to 2.93 per 1,000 person-years, with an aHR of 0.41 (95%CI: 0.27–0.61), compared to non-users. Dulaglutide could significantly decrease risks of both anxiety and depression.Conclusion: Patients with DM receiving GLP1-RA therapy have a greater reduction of the risk of anxiety than that of depression. Our findings strengthen previous research that advocated possible anti-depressant or anxiolytic effects of GLP1-RA and may lead to improved treatment adherence among patients with DM.https://www.frontiersin.org/articles/10.3389/fphar.2022.765446/fulldepressionanxietyglucagon-like peptide-1 receptor agonistdiabetesneuroendocrine |
| spellingShingle | Wen-Hsuan Tsai Fung-Chang Sung Fung-Chang Sung Fung-Chang Sung Lu-Ting Chiu Ying-Hsiu Shih Ming-Chieh Tsai Shu-I Wu Shu-I Wu Decreased Risk of Anxiety in Diabetic Patients Receiving Glucagon-like Peptide-1 Receptor Agonist: A Nationwide, Population-Based Cohort Study Frontiers in Pharmacology depression anxiety glucagon-like peptide-1 receptor agonist diabetes neuroendocrine |
| title | Decreased Risk of Anxiety in Diabetic Patients Receiving Glucagon-like Peptide-1 Receptor Agonist: A Nationwide, Population-Based Cohort Study |
| title_full | Decreased Risk of Anxiety in Diabetic Patients Receiving Glucagon-like Peptide-1 Receptor Agonist: A Nationwide, Population-Based Cohort Study |
| title_fullStr | Decreased Risk of Anxiety in Diabetic Patients Receiving Glucagon-like Peptide-1 Receptor Agonist: A Nationwide, Population-Based Cohort Study |
| title_full_unstemmed | Decreased Risk of Anxiety in Diabetic Patients Receiving Glucagon-like Peptide-1 Receptor Agonist: A Nationwide, Population-Based Cohort Study |
| title_short | Decreased Risk of Anxiety in Diabetic Patients Receiving Glucagon-like Peptide-1 Receptor Agonist: A Nationwide, Population-Based Cohort Study |
| title_sort | decreased risk of anxiety in diabetic patients receiving glucagon like peptide 1 receptor agonist a nationwide population based cohort study |
| topic | depression anxiety glucagon-like peptide-1 receptor agonist diabetes neuroendocrine |
| url | https://www.frontiersin.org/articles/10.3389/fphar.2022.765446/full |
| work_keys_str_mv | AT wenhsuantsai decreasedriskofanxietyindiabeticpatientsreceivingglucagonlikepeptide1receptoragonistanationwidepopulationbasedcohortstudy AT fungchangsung decreasedriskofanxietyindiabeticpatientsreceivingglucagonlikepeptide1receptoragonistanationwidepopulationbasedcohortstudy AT fungchangsung decreasedriskofanxietyindiabeticpatientsreceivingglucagonlikepeptide1receptoragonistanationwidepopulationbasedcohortstudy AT fungchangsung decreasedriskofanxietyindiabeticpatientsreceivingglucagonlikepeptide1receptoragonistanationwidepopulationbasedcohortstudy AT lutingchiu decreasedriskofanxietyindiabeticpatientsreceivingglucagonlikepeptide1receptoragonistanationwidepopulationbasedcohortstudy AT yinghsiushih decreasedriskofanxietyindiabeticpatientsreceivingglucagonlikepeptide1receptoragonistanationwidepopulationbasedcohortstudy AT mingchiehtsai decreasedriskofanxietyindiabeticpatientsreceivingglucagonlikepeptide1receptoragonistanationwidepopulationbasedcohortstudy AT shuiwu decreasedriskofanxietyindiabeticpatientsreceivingglucagonlikepeptide1receptoragonistanationwidepopulationbasedcohortstudy AT shuiwu decreasedriskofanxietyindiabeticpatientsreceivingglucagonlikepeptide1receptoragonistanationwidepopulationbasedcohortstudy |